Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2018
Home
2018
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid Quarterly Operational update
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Record $2M Quarterly Sales for Cellmid’s FGF5 Inhibitors
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Appendix 4C
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Confirmation of Release – CDY – Appendix 4D and Half Year Accounts
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Change of Director’s Interest Notice – Halasz
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid Appoints Dennis Eck Non-Executive Director
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Initial Director’s Interest Notice – Eck
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Change of Director’s Interest Notice – Halasz
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid Signs Distribution Agreement for Fillerina
1
2
3
4
5
6
7
8
Next page
